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Abstract The solution structures of the two compounds of
human uroguanylin (I and II), which were generated during
disulfide bond forming reaction, were found to be topological
isomers by 1H-nuclear magnetic resonance spectroscopy. These
isomers are interconvertible in aqueous media at rates which vary
with the pH and temperature of the solution. Because compound
I is active in the cGMP producing assay, but compound II is not,
this interconversion may be useful for evaluating the activity of
human uroguanylin both in vivo and in vitro.
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1. Introduction
Uroguanylin and guanylin were discovered as endogenous
peptide hormones in mammals based upon their structure
similarity to heat-stable enterotoxins (STs) secreted by patho-
genic bacteria. The primary structures of uroguanylin and
guanylin from human, rat (mouse) and opossum have been
reported as being comprised of 15 or 16 amino acid residues
[1^5] ; the human and rat peptide sequences are shown in Fig.
1. The sequence similarity among them is high and four Cys
residues in all the peptides are conserved. These Cys residues
participate in the formation of the two intramolecular disul-
¢de linkages, one between Cys4 and Cys12 and the other be-
tween Cys7 and Cys15. Uroguanylin and guanylin, as well as
ST, are reported to be involved in the regulation of salt and
water transport in the intestinal tract and kidney. In addition,
these peptides are known to stimulate cGMP production by
activating the guanylyl cyclase C in both enterocytes and T84
colon cancer cells. Therefore, endogenous uroguanylin and
guanylin are suggested to play important roles in intestinal
and renal dysfunction and salt-dependent hypertension [6].
In our previous paper on the chemical synthesis of human
uroguanylin using a two-step selective disul¢de forming meth-
od, two compounds (I and II) were found to be generated
upon analyzing the second disul¢de bond forming reaction
by reversed-phase high performance liquid chromatography
(RP-HPLC) at 40‡C [7]. A typical chromatogram for the sep-
aration of a 1:1 mixture of these compounds is shown in Fig.
2. We have so far clari¢ed the following characteristics for
compounds I and II: (i) each compound can be isolated to
a purity greater than 99% as determined by RP-HPLC; (ii)
both have identical primary structures, molecular weights and
disul¢de connectivity patterns according to examination by
suitable analytical methods; and (iii) signi¢cant di¡erences
exist between them in the optical rotation value and their
biological activity. During the course of our previous study,
Skelton et al. reported that two clearly separable signal con-
nectivities were detected in the analysis of the amino-termi-
nally extended or deleted human guanylin derivatives by nu-
clear magnetic resonance (NMR) spectroscopy. Based on
these observations and structural re¢nements, they proposed
that the heterogeneity of the NMR signals of human guanylin
derivatives originated from the topological isomerism of the
peptide, although such isomers were unseparable on RP-
HPLC under the various analytical conditions used [8]. In con-
trast, we found in a previous study that human des-Leu16-uro-
guanylin and rat guanylin, both of which terminate the peptide
chains at the fourth Cys residue like human guanylin, were
detected as two base-line separable peaks on RP-HPLC when
the analytical temperature was decreased to 8‡C, although these
peptides were eluted in a broad but single peak at 40‡C [7]. From
these observations, we assumed that the two well-separable hu-
man uroguanylin compounds on RP-HPLC were similar topo-
logical isomers with respect to the peptide backbone as reported
for human guanylin derivatives. However, this assumption re-
quired de¢nite con¢rmation by experimental evidence.
In the present study, we analyzed the solution structures of
both compounds by NMR in an aqueous medium to gain
further insight into the characteristics of the isolated com-
pounds I and II of human uroguanylin. We report here con-
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Fig. 1. Primary structures of human and rat uroguanylin and gua-
nylin. Two intramolecular disul¢de linkages are shown at the top of
the sequences.
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¢rmation that the two compounds of human uroguanylin are
indeed topological isomers. We then report on their stability
in solution and in the solid state. These experiments demon-
strate that the topological isomers of human uroguanylin are
not stable in solution and are readily interconvertible,
although they are stable during storage in a freezer as pow-
ders. This has important implications for evaluating the bio-
logical activity of human uroguanylin because compound I
elicits the activity in the cGMP production assay, whereas
compound II primarily aborts it [9].
2. Materials and methods
2.1. Peptide synthesis
Two compounds (I and II) of human uroguanylin were obtained
following the reported procedure [7]. Brie£y, the protected peptide
was elongated on resin using an ABI 430A peptide synthesizer by
applying Boc/Bzl chemistry. Pairs of the Cys residues which form
intramolecular disul¢de bonds were selectively protected by orthogo-
nally cleavable groups, 4-methylbenzyl and acetamidomethyl. After
treatment with anhydrous hydrogen £uoride, two intramolecular di-
sul¢de bonds were formed successively with K3[Fe(CN)6] and then
with iodine. Two compounds generated during the second disul¢de
bond formation in MeOH/50% AcOH (1:1, v/v) were isolated by RP-
HPLC, lyophilized and stored in a freezer until use. Human des-
Leu16-uroguanylin, rat guanylin and rat uroguanylin-15 were synthe-
sized by applying the same strategy as for human uroguanylin. The
resulting major peaks from RP-HPLC were isolated at 40‡C and
stored in a freezer after the usual workup including lyophilization.
2.2. CD measurement
The CD spectrum was recorded on a JASCO J720 spectropolarim-
eter with a cell path length of 0.1 cm at 25‡C. The sample was dis-
solved in 10 mM sodium phosphate bu¡er at pH 7.0 at a concentra-
tion of 100 WM.
2.3. NMR measurement and structure calculation
All the spectra were recorded on a Bruker DRX-500 spectrometer
at 10‡C. The peptide was dissolved in 10 mM sodium phosphate at
pH 3.7 containing 10% deuterated water (D2O) at a peptide concen-
tration of 5 mM. Assignment of proton resonances was achieved
according to the standard method developed by Wuºthrich [10]. The
nuclear Overhauser e¡ect (NOE) distance constraints for compounds
I and II were derived from two-dimensional NOESY spectra acquired
for 24 h with mixing times of 120 and 250 ms, respectively. All the
structure calculations were performed with the program X-PLOR.
2.4. RP-HPLC analysis
RP-HPLC was performed on a Shimadzu Model LC-6A with a
YMC ODS column (4.6U150 mm). Standard conditions for analyses
of the two compounds of human uroguanylin were isocratic elution at
25.5% acetonitrile in 0.1% TFA at 40‡C. Analyses of 15-residue gua-
nylin and uroguanylin derivatives were carried out both at 40‡C and
8‡C under linear gradient conditions; 1% to 60% acetonitrile (25 min)
in 0.1% TFA. Absorbance was monitored at 220 nm.
2.5. Stability of compounds I and II in solution
Each isolated compound of human uroguanylin was dissolved in
50% AcOH, 0.05% TFA or 50 mM NH4OAc at pH 7.7 containing
0.25 M guanidine hydrochloride (GdnHCl) at a concentration of
1 mg/200 Wl. Half of each prepared solution was incubated at 37‡C
and the remaining half was kept at ambient temperature (15^20‡C). In
the case of the analysis in the presence of N-ethylmaleimide (NEM), each
compound was dissolved in the same bu¡er as above at pH 7.7 which
contains a slight molar excess amount of NEM. The change in purity
of each peptide was analyzed at 24 h intervals by RP-HPLC. The
amount of each compound in the individual solution was calculated
by integration of the corresponding peak areas on the chromatogram.
2.6. Bioassay
Accumulation of cGMP in T84 cells was measured following a
reported procedure [9].
3. Results
3.1. Solution structure of compounds I and II of human
uroguanylin
In order to elucidate the secondary structure di¡erence be-
tween compounds I and II of human uroguanylin, CD spectra
of each compound were recorded at pH 7.0 (Fig. 3). A neg-
ative band around 200 nm was detected for both compounds,
but the ellipticity was much greater in compound I, suggesting
a di¡erence in their structures.
Further structural analysis of the two compounds was car-
ried out by NMR in 10 mM sodium phosphate at pH 3.7 and
10‡C. From the distance constraints elucidated from the NOE
data, the ensembles of 10 solution structures of compounds I
and II were deduced with reasonably good convergence
(RMSDs for compounds I and II backbone atoms are
0.67 Aî and 0.48 Aî , respectively) if the less well-de¢ned ami-
no-terminal 3-residues and the carboxyl-terminal Leu residue
were excluded. The energy-minimized average structures of
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Fig. 2. Separation of the isolated compounds I and II of human ur-
oguanylin (1:1 mixture) on RP-HPLC under isocratic conditions.
See Section 2 for details of the analytical conditions.
Fig. 3. CD spectra of compounds I and II of human uroguanylin in
10 mM sodium phosphate at pH 7.0.
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compounds I and II are shown in Fig. 4. Both favored struc-
tures are depicted by ¢xing the loop structure composed of the
residues 7^12 (central loop) to have the same spatial arrange-
ment at their bottoms. As is obvious from the deduced struc-
ture of compound I shown in Fig. 4a, one segment comprising
the amino-terminal residues 1^7 and the disul¢de bond be-
tween Cys4 and Cys12 is located at the left top side of the
central loop and another segment encompassing the carboxyl-
terminal residues 12^16 and the disul¢de bond between Cys7
and Cys15 is at the right top side. In contrast, the structure of
compound II, shown in Fig. 4b, revealed that the above two
segments extend outwards and directly opposite from the cen-
tral loop. Therefore, the solution structure di¡erence between
the two compounds lies merely in the orientation of these two
segments from the central loop, clearly demonstrating that the
well-separable two compounds of human uroguanylin on RP-
HPLC are topological isomers.
3.2. Stability of compounds I and II of human uroguanylin
Compounds I and II have distinctly di¡erent retention
times on RP-HPLC at 40‡C, and thus could be separately
isolated at purities greater than 99%. The purities of the iso-
lated compounds were con¢rmed to be maintained for more
than one year when each compound was stored in a freezer as
an amorphous powder. However, mutual contamination,
comprising 0.8% of the total peak areas, was seen when the
purities of the isolated compounds were evaluated by RP-
HPLC after the compounds were lyophilized from 0.1%
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Fig. 4. Average favored solution structures of compound I (a) and compound II (b) of human uroguanylin.
Fig. 5. Time course analyses of conversion of compound I (a) and compound II (b) of human uroguanylin in solution. The purity change of
each compound was monitored by RP-HPLC under isocratic conditions. The peak area of each converted compound was shown as a % of the
sum of those for compounds I and II on the individual chromatogram.
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TFA solution. These results suggest that while the two com-
pounds are stable once they are isolated and stored as pow-
ders at below 320‡C, their stability may be less in solution,
that is, compounds I and II are interconvertible in solution.
To examine whether such interconversion occurred during the
synthesis and analysis, the degree of purity of each compound
in 50% AcOH, 0.05% TFA and 50 mM NH4OAc (pH 7.7)
containing 0.25 M GdnHCl was analyzed by RP-HPLC.
These solvents were chosen as mimicking the media employed
for disul¢de bond formation, puri¢cation of the oxidized pep-
tides by RP-HPLC and measurement of the biological activ-
ity, respectively. Each solution was kept at both ambient tem-
perature (15^20‡C) and 37‡C.
RP-HPLC analyses of the constructed solutions of com-
pounds I and II showed that the peak area of the starting
compound decayed gradually and that of the converted ma-
terial (compound I in the case of compound II and vice versa)
increased comprehensively in all the media we examined. This
clearly demonstrates that the interconversion of the two com-
pounds indeed takes place in solution. The results of the anal-
yses of the interconversion for each compound are summar-
ized in Fig. 5 as a function of time. In the acidic milieu (0.05%
TFA and 50% AcOH), the conversions proceeded in an al-
most comparable manner for both compounds. The slopes of
the conversion rate in 0.05% TFA, however, were steeper than
those in 50% AcOH, that is, the conversion from compound I
to compound II and vice versa at 37‡C in 0.05% TFA was
complete and resulted in a steady state in 2 days, whereas
more than 4 days were required for the same processes in
50% AcOH. The temperature dependence of the conversion
was observed in both acidic media, in which the rate of the
interconversion was always faster at 37‡C than that at room
temperature (15^20‡C).
In 50 mM NH4OAc bu¡er at pH 7.7, both compounds
were generally more stable (slower conversion) than in acidic
milieu. However, in contrast to the results in the two acidic
solvents, their conversion rates were not identical in this neu-
tral bu¡er, that is, compound I was converted more slowly
than compound II. In addition, the slope of the conversion
rate of compound I at pH 7.7 and 37‡C was found to be lower
than that in 0.05% TFA at ambient temperature. This rank
order alteration in neutral bu¡er is distinct from all other
experiments because regardless of the starting compounds,
preferential conversion rates were always observed at 37‡C
except for this particular case.
The above results de¢nitely demonstrate that the two com-
pounds are interconvertible in solution, therefore, it is tempt-
ing to conjecture that disul¢de linkage scission and reclosure
is involved in the mechanism of the conversion. In order to
address this, a stability test was done using the same bu¡er as
above at pH 7.7, except NEM, a well-known SH trapping
reagent, was added. Analysis by RP-HPLC showed that the
slope of the conversion in the presence of NEM could be
completely superimposed on that in its absence (data not
shown), indicating that disul¢de bond opening does not occur
during the conversion.
4. Discussion
Structure analyses of two compounds (I and II) of human
uroguanylin by NMR were carried out in both dimethyl sulf-
oxide (DMSO) and aqueous solutions. Distinct chemical shifts
were observed for both compounds in either medium, but
more HK-signal overlapping was detected in DMSO. There-
fore, the aqueous solution structures of the two compounds of
human uroguanylin were re¢ned with a simulated annealing
protocol, by which they were de¢nitely con¢rmed to be topo-
logical isomers. The elucidated backbone structure of the iso-
lated compound I (a biologically active component) is similar
to that of the reported human guanylin isomer ‘A-form’,
which was determined in the mixture of the two topological
isomers [8], as well as that of heat-stable enterotoxin (ST) with
three disul¢de bonds [11]. Although it has not been clari¢ed as
to whether the human guanylin ‘A-form’ is a biologically ac-
tive component or not, the similar backbone topology among
these family peptides may be a prerequisite for expressing the
cGMP producing activity. Analyses of the side chain orienta-
tion of the two compounds of human uroguanylin is now
underway in our laboratory, however, in a preliminary result,
side chain location in the putative active site region around
Ala11, which is estimated from the active site of ST reported
by Shimonishi et al. [12], seems to be di¡erent from each other
(data not shown). Results of these analyses together with the
experimental data for three-dimensional backbone structure
resolution will be reported in the near future (T. Yoshida et
al., manuscript in preparation).
In the RP-HPLC analyses of the two human uroguanylin
isomers, we had already established that they are separable at
40‡C. However, separations of the human des-Leu16-urogua-
nylin isomers, as well as the rat guanylin isomers, were pos-
sible only at lower temperatures such as 8‡C [7]. This separa-
tion characteristic has also been observed for a recently
disclosed member of the uroguanylin and guanylin peptide
family, rat uroguanylin-15 (unpublished result). Considering
that the latter three peptides are composed of 15 residues with
the sequence ending at the fourth Cys residue, we con¢rmed
that the Leu residue at position 16 of human uroguanylin
endows the topological isomers with a separation e⁄ciency
signi¢cantly higher than the other shorter uroguanylin and
guanylin family peptides on RP-HPLC. In other words, the
topological isomers of human uroguanylin may be stabilized
signi¢cantly by the Leu residue lying outside the disul¢de-
linked loop structure.
As far as we know, including the case of human guanylin
[8], few features have been characterized to date for the iso-
lated individual topological isomers. In the present study, we
have shown that these isomers of human uroguanylin are
interconvertible without disul¢de bond opening when left
standing in solution over a period of time (days). Analyses
of the stability of the two compounds at acidic and neutral
pH values suggest that the conversion rates are a¡ected by the
ionization state of functional group(s) in the molecule. At
acidic pH, both compounds are, in one sense, freely conver-
tible (same conversion rates) and eventually come to a 1:1
equilibrium ratio. In contrast, conversions of both compounds
at pH 7.7 seem to be hampered and thereby their rates are
signi¢cantly decreased, especially for compound I. A more
extensive analysis of the pH-dependent conversion rates of
the two isomers is now underway in our laboratory.
In the NMR study of human guanylin derivatives reported
by Skelton et al. [8], they commented on the interconversion
of the topological isomers: (i) based on line broadening ex-
periments at high temperature, the exchange must be very
slow with a half-life of seconds or longer, and (ii) in restrained
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molecular dynamics (MD) calculations, transition from one
state to the other could not be induced with a realistic force
¢eld. In the present study, we observed by RP-HPLC analyses
that the half-life of interconversion of the two human urogua-
nylin isomers in 0.05% TFA at 37‡C was about 1 day; these
are the conditions under which the interconversion proceeds
fastest. In the case of the human des-Leu16-uroguanylin topo-
logical isomers, they were more unstable than those of the
parental peptide because they were mutually contaminated
by approximately 20^30% after isolation by RP-HPLC at
8‡C and subsequent concentration of the solvent at room
temperature for 2 h (preliminary data). This phenomenon is
also observed for rat uroguanylin-15, demonstrating that the
topological isomers of the peptides with the fourth Cys resi-
due at their carboxyl termini survive as a main fraction after 2
h even though the interconversion rate is faster than for hu-
man uroguanylin. These observations con¢rm that the inter-
conversion rates of the topological isomers of uroguanylin
and guanylin family peptides are much longer than that of
NMR and MD time scales.
We have already reported that (i) in the chemical synthesis
of human uroguanylin, the ratio of the topological isomers
(compounds I and II) di¡ers signi¢cantly with the order of
the two intramolecular disul¢de bond forming reactions, and
that (ii) compound I shows signi¢cant activity in the cGMP
producing assay, whereas compound II is practically inactive
[7,9]. We have further clari¢ed recently that compound I iso-
lated after conversion from the inactive component, com-
pound II, is fully active. Furthermore, compound II is a
weak agonist without antagonistic activity because the
cGMP production in T84 cells by the simultaneous stimula-
tion with both compounds was equivalent to the sum of the
individual stimulations (data not shown). In the former chem-
ical synthesis, the second disul¢de bond forming reaction pro-
ceeded very quickly (less than 20 min) and the reaction mix-
ture was analyzed immediately after quenching of the reaction
with ascorbic acid. In the latter case, measurement of the
biological activity was performed using freshly prepared sol-
ution of each compound and the response in T84 cells was not
retarded. Therefore, we are certain that all these ¢ndings are
correct even though the two compounds are interconvertible
in solution. We have also elucidated the endogenous molec-
ular form of uroguanylin in humans by the combined analyses
of RP-HPLC and radioimmunoassay using antibodies speci¢c
for each topological isomer [9]. As relatively long times and
procedures were required for the isolation and quanti¢cation
of the two isomers in the body, it is conceivable that the
interconversion may occur during the course of the analysis.
Actually, a low level of mutual cross-reactivity contamina-
tions (3^3.5%) in each of the speci¢c antibodies were observed
during characterization of the speci¢city of the respective anti-
bodies using two 125I-Tyr0-human uroguanylin isomers as
tracers. This implies the possible conversion of the two iso-
mers of the standard and/or radio-labeled peptides, although
such cross-reactivity might be an intrinsic feature of the anti-
bodies. Nonetheless, this does not invalidate the reported re-
sults concerning the endogenous form and amount of human
uroguanylin because care was always taken during each ex-
perimental step to detect the occurrence of the conversion and
to minimize experimental errors by keeping the peptide solu-
tions at as a low temperature as possible. In the above NMR
experiments, the structures of both compounds were deter-
mined without serious mutual contamination of signals prob-
ably because the measurements were carried out at a low
temperature of 10‡C.
In the present study, we found that human uroguanylin
tends to isomerize topologically in solution, resulting in a
mixture of the biologically active and inactive isomers. Inter-
estingly, the 24-amino acid peptide with an 8-residue exten-
sion at the amino terminus of human uroguanylin could be
isolated from hemo¢ltrate pools and was found to accumulate
cGMP in T84 cells, that is, amino-terminally extended human
uroguanylin is a biologically active form [13]. In the case of
rat guanylin, its precursor with 94 amino acid residues as well
as the amino-terminally Asp extended peptide with 16 amino
acid residues are both biologically inactive [14]. Most of the
biologically active 15-residue peptide of rat guanylin is re-
ported to be generated by the arti¢cial cleavage at the Asp-
Pro bond in the precursor during the isolation process with
hot AcOH [15]. Taken together, we speculate that exertion of
the biological activity of the uroguanylin and guanylin family
peptides is primarily determined by two factors: (1) peptide
chain length and (2) topological isomerization.
Finally, we emphasize that the biological activity data of
human uroguanylin and its derivatives, regardless of whether
they are synthetic or natural products, may lead to confusing,
variable potency results if the data are obtained after the
peptide solutions have been left at room temperature for a
few days, especially under acidic conditions.
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